The announcement follows the recent signing of a $27 million agreement to guarantee Covid-19 vaccines for half the population from the COVAX facility.
Last month, J&J said its experimental COVID-19 vaccine produced a strong immune response against the novel coronavirus in an early-to-mid stage clinical trial, following which the company kicked off a final 60,000-person trial, whose results had been expected by the end of this year or early 2021.
"When a potentially unexplained illness occurs in a trial participant, which may or may not be related to the vaccine being evaluated, it is rigorous, routine practice to investigate", the spokesperson said.
On Monday, Johnson & Johnson said that it has temporarily paused its COVID-19 vaccine candidate clinical trials due to an unexplained illness in a study participant.
"We're expecting that early next year we should have the vaccine in the country from maybe more than one source".
"Safety is the primary focus for vaccine clinical trials. Our hope is that, subject to clinical and regulatory success, our vaccine will make this happen", Harris said.
China acts to slow yuan's rapid ascent without halting its rise
The S&P 500 rose 36 points, or 1.05%, to 3,513.26, while the Dow Jones Industrial Average rose 179 points, or 0.63%, to 28,763.12. Despite its strong progress, China was notably not a participant in the report.
Elderly people are also vulnerable - and researchers want more over-65s to volunteer for vaccine trials too.
Participants will be given either the BCG vaccine, now provided to more than 100 million babies worldwide each year, including in India, to protect against TB or a placebo injection.
Like several other Phase 3 trials that are underway, its primary objective is to test whether the vaccine can prevent symptomatic Covid-19.
BioNtech and Pfizer, AstraZeneca and the University of Oxford, US-based Moderna (MRNA), Novavax (NVAX), Johnson&Johnson (JNJ), and Germany's CureVac (CVAC) are frontrunners in the vaccine-development race.
According to officials, the Hyderabad-based vaccine maker applied to the Drugs Controller General of India (DCGI) on October 2, seeking its permission to conduct phase III randomised, double-blind placebo-controlled multicentre trial of its COVID-19 vaccine candidate.